Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06496542 · ClinicalTrials.gov registry record · NA
Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD
A NA study of Autosomal Dominant Polycystic Kidney, sponsored by University of Colorado, Denver.
- Active
- Registry status
- NA
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT06496542 is a NA study of Autosomal Dominant Polycystic Kidney that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 16 participants, below the 102-participant average among 6 other Autosomal Dominant Polycystic Kidney trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06496542, a NA study of Autosomal Dominant Polycystic Kidney, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed research is a pilot study assessing kidney oxidative metabolism and insulin sensitivity after a 2-year weight loss intervention in those with autosomal dominant polycystic kidney disease who are overweight or obese.
Conditions Studied
Interventions
- BEHAVIORAL Daily caloric restriction
- OTHER Standard advice control
Study Locations (1)
Colorado
- University of Colorado- Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-01-13 |
| Est. Completion | 2026-07-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06496542
The ClinicalTrials.gov registry entry for NCT06496542 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 102-participant average among 6 other Autosomal Dominant Polycystic Kidney trials with a reported enrollment target (84% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autosomal Dominant Polycystic Kidney appearing as the primary indexed condition, and to 2 interventions - of which Daily caloric restriction is the first listed.
NCT06496542 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT06496542 about?
NCT06496542 is a clinical study titled "Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD". The proposed research is a pilot study assessing kidney oxidative metabolism and insulin sensitivity after a 2-year weight loss intervention in those with autosomal dominant polycystic kidney disease who are overweight or obese.
What is the current status of trial NCT06496542?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2023-01-13. Estimated completion is 2026-07-01.
What conditions does trial NCT06496542 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney.
What interventions are being tested in trial NCT06496542?
The interventions under investigation include: Daily caloric restriction (BEHAVIORAL), Standard advice control (OTHER).
Who is sponsoring clinical trial NCT06496542?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06496542 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Daily Caloric Restriction in ADPKD
ACTIVE NOT RECRUITING · NA
-
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease
COMPLETED · NA
-
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
RECRUITING · Phase 2
-
A Prospective Observational Study of Foam Sclerotherapy .
RECRUITING
-
Statin Therapy in Patients With Early Stage ADPKD
ACTIVE NOT RECRUITING · Phase 4
-
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.